Euploid Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 6.00 Cr
as on 31-07-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.18 Cr
as on 31-07-2024
- Revenue 3.58%
(FY 2023)
- Profit -283.91%
(FY 2023)
- Ebitda 17.91%
(FY 2023)
- Net Worth 693.18%
(FY 2023)
- Total Assets 197.68%
(FY 2023)
About Euploid Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 6.00 Cr.
The company currently has active open charges totaling ₹15.18 Cr.
Raju Raghavendra and Nagarani serve as directors at the Company.
- CIN/LLPIN
U24230KA2015PTC081999
- Company No.
081999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Euploid Pharmaceuticals Private Limited offer?
Euploid Pharmaceuticals Private Limited offers a wide range of products and services, including Sexual Wellness Products, Fertility Enhancer, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Cardiovascular Drugs & Medication, Diabetes Medicine.
Who are the key members and board of directors at Euploid Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raju Raghavendra  | Director | 04-Aug-2015 | Current |
| Nagarani | Additional Director | 07-Jun-2024 | Current |
Financial Performance of Euploid Pharmaceuticals.
Euploid Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.58% increase. The company also saw a substantial fall in profitability, with a 283.91% decrease in profit. The company's net worth Soared by an impressive increase of 693.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Euploid Pharmaceuticals?
In 2023, Euploid Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aryvenk Pharmatech Global Solutions Private LimitedActive 2 years 4 monthsRaju Raghavendra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 16 Feb 2022 | ₹15.18 Cr | Open |
How Many Employees Work at Euploid Pharmaceuticals?
Unlock and access historical data on people associated with Euploid Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Euploid Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Euploid Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
